![Olivier Martinez](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Olivier Martinez
Direttore/Membro del Consiglio presso
INNATE PHARMA
Profilo
Dr. Olivier Martinez is an Investment Director at BPIFrance Investissement SAS, a Chairman at SA Seridis and a Chairman & Chief Executive Officer at Société d'Amenagement des Territoires et d'Equipement.
He is on the Board of Directors at ABIONYX Pharma SA, Innate Pharma SA and Alizé Pharma SARL. Dr. Martinez was previously employed as an Investment Director by CDC Entreprises Valeurs Moyennes SAS, an Investment Director by Cdc Entreprises SAS, a Director-Investments & Member-Management Board by Bioam Gestion SA, a Partner by Bioam Gestion SA, a Chairman by Cytheris SA, a Member-Supervisory Board by Emergence Therapeutics AG, and a Member-Supervisory Board by Genticel SA. He also served on the board at Adocia SA, Poxel SA, Innate Pharma SA, FAB Pharma SAS, HalioDx SASU and Millendo Therapeutics SAS. He received his undergraduate degree from École Normale Supérieure and an MBA from the College des Ingenieurs.
Posizioni attive di Olivier Martinez
| Società | Posizione | Inizio |
|---|---|---|
| ABIONYX PHARMA SA | Direttore/Membro del Consiglio | 20/07/2010 |
| INNATE PHARMA | Direttore/Membro del Consiglio | 30/06/2021 |
Alizé Pharma SARL | Direttore/Membro del Consiglio | - |
Société d'Amenagement des Territoires & d'Equipement des
 Société d'Amenagement des Territoires & d'Equipement des Engineering & ConstructionIndustrial Services Provides civil engineering construction work services | Amministratore Delegato | - |
SA Seridis
 SA Seridis Food RetailRetail Trade Operates supermarkets | Presidente | - |
BPIFrance Investissement SAS
 BPIFrance Investissement SAS Investment ManagersFinance BPIfrance Investissement is an active manager focused on small, medium and intermdiate-sized businesses with high-growth potential. They favor sectors related to industry and technology and focus on investments in France. The firm invests either directly through dedicated investment funds or indirectly through private equity funds, partnerships and fund of funds managed by third parties. They invest across development stages, from start-ups to small LBO operations resulting from corporate succession issues. Their deal-sourcing process is both regional and national. | Investitore di Private Equity | 14/10/2010 |
Precedenti posizioni note di Olivier Martinez
| Società | Posizione | Fine |
|---|---|---|
| ADOCIA | Direttore/Membro del Consiglio | 01/12/2022 |
| INNATE PHARMA | Direttore/Membro del Consiglio | 02/06/2016 |
CDC Croissance SA
 CDC Croissance SA Investment ManagersFinance CDC Croissance develops an investment strategy for their clients based on each client's financial goals, time horizon and risk tolerance. | Direttore degli Investimenti | 01/01/2013 |
| ░░░ ░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░ ░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Olivier Martinez
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
76
Relazioni di 1° grado
20
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 20 |
|---|---|
Poxel SA
 Poxel SA Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company, focuses on the development of novel treatments for serious chronic diseases | Health Technology |
Bioam Gestion SA
 Bioam Gestion SA Investment ManagersFinance BG is a venture capital investment management firm specialized in early-stage financing of biotechnology companies. They target start-ups with high growth potential, spawned by French and European public or private sector life science research, and more particularly applications in the healthcare, environment, agricultural and food industries. Within the healthcare sector BG focuses on biopharmaceuticals, medical instrumentation and diagnosis systems. BG provides seed capital, generally investing in the first institutional round of financing, and later participating in subsequent rounds. The firm usually joins forces with French or foreign co-investors. BG invests in France and in Europe. The firm sources deals through their extensive network in the French academic community and in the biopharmaceutical industry. BG is an active investor who sits on the board and provides strategic advisory as well as development assistance to their portfolio companies. | Finance |
Innate Pharma SA
 Innate Pharma SA Pharmaceuticals: MajorHealth Technology Develops therapeutic antibodies that harness the immune system to improve cancer treatment and clinical outcomes | Health Technology |
Cytheris SA
 Cytheris SA Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for immune modulation | Health Technology |
ABIONYX Pharma SA
 ABIONYX Pharma SA Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes novel HDL therapies for the treatment of cardiovascular and metabolic diseases | Health Technology |
Université de Paris XI Paris Sud
 Université de Paris XI Paris Sud Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
École Normale Supérieure
 École Normale Supérieure Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BPIFrance Investissement SAS
BPIFrance Investissement SAS Investment ManagersFinance BPIfrance Investissement is an active manager focused on small, medium and intermdiate-sized businesses with high-growth potential. They favor sectors related to industry and technology and focus on investments in France. The firm invests either directly through dedicated investment funds or indirectly through private equity funds, partnerships and fund of funds managed by third parties. They invest across development stages, from start-ups to small LBO operations resulting from corporate succession issues. Their deal-sourcing process is both regional and national. | Finance |
CDC Croissance SA
CDC Croissance SA Investment ManagersFinance CDC Croissance develops an investment strategy for their clients based on each client's financial goals, time horizon and risk tolerance. | Finance |
Genticel SA
 Genticel SA BiotechnologyHealth Technology Develops vaccines for patients infected with human papillomavirus | Health Technology |
Adocia SA
 Adocia SA Pharmaceuticals: MajorHealth Technology Manufactures novel therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases | Health Technology |
Millendo Therapeutics SAS
 Millendo Therapeutics SAS Medical SpecialtiesHealth Technology Provides pharmaceutical research services | Health Technology |
FAB Pharma SAS
 FAB Pharma SAS Miscellaneous Commercial ServicesCommercial Services Develops drugs for the treatments of bacterial infections | Commercial Services |
SA Seridis
SA Seridis Food RetailRetail Trade Operates supermarkets | Retail Trade |
College des Ingenieurs
 College des Ingenieurs Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
HalioDx SASU
 HalioDx SASU BiotechnologyHealth Technology Engages in research and development of immuno-oncology diagnostics | Health Technology |
Cdc Entreprises SAS
 Cdc Entreprises SAS Investment ManagersFinance Operates as a private equity fund | Finance |
Emergence Therapeutics AG
 Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company which develops novel antibody drugs | Health Technology |
Alizé Pharma SARL | |
Société d'Amenagement des Territoires & d'Equipement des
Société d'Amenagement des Territoires & d'Equipement des Engineering & ConstructionIndustrial Services Provides civil engineering construction work services | Industrial Services |
